Skip to main content
Clinical Trials/IRCT20200324046851N2
IRCT20200324046851N2Not yet recruitingPhase 3

Evaluation of gene expression, methylation and secretory level of cytokines and inflammatory chemokines in COPD patients receiving nanocurcumin supplementation compared with patients receiving placebo

Tabriz University of Medical Sciences0 sites30 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Not yet recruiting
Enrollment
30

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
no limit to no limit (—)
Sex
All

Inclusion Criteria

  • Diagnosed with COPD with stage B, C, or D according to GOLD 2019..
  • Age between 40-75 years old.
  • Both genders.
  • Smoker or less than 6 months of smoking cessation time

Exclusion Criteria

  • Asthma and other pulmonary-related diseases and injuries (including lung tuberculosis, restrictive lung disease, idiopathic pulmonary fibrosis, or lung cancer).
  • Acute and/or active infection.
  • Patients with complex cardiovascular diseases (including valvular heart disease, cardiomyopathy, arrhythmia, congenital heart disease, hypertrophy syndrome).
  • Liver and kidney failure.
  • Patients with life expectancy less than 6 months due to concomitant illness.
  • Under immunosuppressive treatment within 8 weeks of the first screening visit

Investigators

Similar Trials

Evaluation of gene expression, methylation... | Clinical Trial